OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022
Milena Suarez Castillo, Hamid Khaoua, Noémie Courtejoie
Eurosurveillance (2022) Vol. 27, Iss. 16
Open Access | Times Cited: 41
Milena Suarez Castillo, Hamid Khaoua, Noémie Courtejoie
Eurosurveillance (2022) Vol. 27, Iss. 16
Open Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113522-113522
Open Access | Times Cited: 93
Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113522-113522
Open Access | Times Cited: 93
A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 34
Hassen Mohammed, Dan Duy Pham-Tran, Zi Yi Michelle Yeoh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 224-224
Open Access | Times Cited: 34
Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 36-42
Open Access | Times Cited: 22
Anne J. Huiberts, Brechje de Gier, Christina E. Hoeve, et al.
International Journal of Infectious Diseases (2023) Vol. 133, pp. 36-42
Open Access | Times Cited: 22
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022
Jesús Castilla, Óscar Lecea, Carmen Martín Salas, et al.
Eurosurveillance (2022) Vol. 27, Iss. 33
Open Access | Times Cited: 27
Jesús Castilla, Óscar Lecea, Carmen Martín Salas, et al.
Eurosurveillance (2022) Vol. 27, Iss. 33
Open Access | Times Cited: 27
Michelle Giles, Katie L. Flanagan
Internal Medicine Journal (2024) Vol. 54, Iss. 3, pp. 368-373
Open Access | Times Cited: 5
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024
Guiling Zhou, Nina Dael, Stefan Verweij, et al.
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240222-240222
Open Access
Guiling Zhou, Nina Dael, Stefan Verweij, et al.
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240222-240222
Open Access
Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection
Bette Liu, Heather F. Gidding, Sandrine Stepien, et al.
Vaccine (2022) Vol. 40, Iss. 43, pp. 6288-6294
Open Access | Times Cited: 24
Bette Liu, Heather F. Gidding, Sandrine Stepien, et al.
Vaccine (2022) Vol. 40, Iss. 43, pp. 6288-6294
Open Access | Times Cited: 24
COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups
Sherrie L. Kelly, Epke A. Le Rutte, Maximilian Richter, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 5, pp. 2045-2061
Open Access | Times Cited: 22
Sherrie L. Kelly, Epke A. Le Rutte, Maximilian Richter, et al.
Infectious Diseases and Therapy (2022) Vol. 11, Iss. 5, pp. 2045-2061
Open Access | Times Cited: 22
Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination
Elena Varea-Jiménez, Esteban Aznar Cano, Lorena Vega‐Piris, et al.
Enfermedades infecciosas y microbiologia clinica (English ed ) (2023) Vol. 42, Iss. 4, pp. 187-194
Open Access | Times Cited: 15
Elena Varea-Jiménez, Esteban Aznar Cano, Lorena Vega‐Piris, et al.
Enfermedades infecciosas y microbiologia clinica (English ed ) (2023) Vol. 42, Iss. 4, pp. 187-194
Open Access | Times Cited: 15
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities
Mohammad Shah Alam
Heliyon (2023) Vol. 9, Iss. 2, pp. e13285-e13285
Open Access | Times Cited: 15
Mohammad Shah Alam
Heliyon (2023) Vol. 9, Iss. 2, pp. e13285-e13285
Open Access | Times Cited: 15
Repeated mRNA vaccination sequentially boosts SARS-CoV-2-specific CD8+ T cells in persons with previous COVID-19
Emily S. Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Nature Immunology (2023) Vol. 25, Iss. 1, pp. 166-177
Open Access | Times Cited: 14
Emily S. Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Nature Immunology (2023) Vol. 25, Iss. 1, pp. 166-177
Open Access | Times Cited: 14
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Sharon Walmsley, Majid Nabipoor, Freda Qi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
Sharon Walmsley, Majid Nabipoor, Freda Qi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines
Peifang Sun, Corey A. Balinsky, Le Jiang, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 2, pp. 149-159
Open Access | Times Cited: 7
Peifang Sun, Corey A. Balinsky, Le Jiang, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 2, pp. 149-159
Open Access | Times Cited: 7
Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)
Philipp Köhler, Baharak Babouee Flury, Sabine Güsewell, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 6
Open Access | Times Cited: 7
Philipp Köhler, Baharak Babouee Flury, Sabine Güsewell, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 6
Open Access | Times Cited: 7
Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: A systematic review and meta-analysis
Tim K. Tsang, Sheena G. Sullivan, Xiaotong Huang, et al.
American Journal of Epidemiology (2024) Vol. 193, Iss. 12, pp. 1868-1881
Open Access | Times Cited: 2
Tim K. Tsang, Sheena G. Sullivan, Xiaotong Huang, et al.
American Journal of Epidemiology (2024) Vol. 193, Iss. 12, pp. 1868-1881
Open Access | Times Cited: 2
Hybrid and vaccine‐induced immunity against SAR‐CoV ‐2 in MS patients on different disease‐modifying therapies
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 10, pp. 1643-1659
Open Access | Times Cited: 11
Ilya Kister, Ryan Curtin, Jinglan Pei, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 10, pp. 1643-1659
Open Access | Times Cited: 11
Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination
Elena Varea-Jiménez, Esteban Aznar Cano, Lorena Vega‐Piris, et al.
Enfermedades Infecciosas y Microbiología Clínica (2022) Vol. 42, Iss. 4, pp. 187-194
Open Access | Times Cited: 11
Elena Varea-Jiménez, Esteban Aznar Cano, Lorena Vega‐Piris, et al.
Enfermedades Infecciosas y Microbiología Clínica (2022) Vol. 42, Iss. 4, pp. 187-194
Open Access | Times Cited: 11
Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case–Control Study Based on the French National Health Data System
Laura Semenzato, Jérémie Botton, Stéphane Le Vu, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 4
Laura Semenzato, Jérémie Botton, Stéphane Le Vu, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 4
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination
Sharon Walmsley, Majid Nabipoor, Leif E. Lovblom, et al.
Vaccines (2023) Vol. 12, Iss. 1, pp. 36-36
Open Access | Times Cited: 4
Sharon Walmsley, Majid Nabipoor, Leif E. Lovblom, et al.
Vaccines (2023) Vol. 12, Iss. 1, pp. 36-36
Open Access | Times Cited: 4
Risk of SARS-CoV-2 infection and hospitalization in individuals with natural, vaccine-induced and hybrid immunity: a retrospective population-based cohort study from Estonia
Anneli Uusküla, Heti Pisarev, Anna Tisler, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Anneli Uusküla, Heti Pisarev, Anna Tisler, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study
Marcelo Wolff, Paulo Charpentier, Andrea Canals, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 671-676
Open Access | Times Cited: 3
Marcelo Wolff, Paulo Charpentier, Andrea Canals, et al.
Vaccine (2023) Vol. 42, Iss. 3, pp. 671-676
Open Access | Times Cited: 3
CD8+ T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccination
Emily S. Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 4
Emily S. Ford, Koshlan Mayer-Blackwell, Lichen Jing, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 4
Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative study: A systematic review and meta-analysis
Tim K. Tsang, Sheena G. Sullivan, Xiaotong Huang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Tim K. Tsang, Sheena G. Sullivan, Xiaotong Huang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 4
Primary and booster vaccination in reducing severe clinical outcomes associated with Omicron Naïve infection
Chen-Yang Hsu, Jung‐Chen Chang, Sam Li-Shen Chen, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 1, pp. 55-63
Open Access | Times Cited: 4
Chen-Yang Hsu, Jung‐Chen Chang, Sam Li-Shen Chen, et al.
Journal of Infection and Public Health (2022) Vol. 16, Iss. 1, pp. 55-63
Open Access | Times Cited: 4
Building energy efficiency and COVID-19 infection risk: Lessons from office room management
Nan Zhang, Tingrui Hu, Menghan Niu, et al.
Building Simulation (2023) Vol. 16, Iss. 8, pp. 1425-1438
Closed Access | Times Cited: 2
Nan Zhang, Tingrui Hu, Menghan Niu, et al.
Building Simulation (2023) Vol. 16, Iss. 8, pp. 1425-1438
Closed Access | Times Cited: 2
